who european region

 {Photo credit: Durmuş Şahin}(left to right) Dr. Raed Arafat, Chair of the Conference, Secretary of State, Ministry of Health of Romania; Dr. Martin van den Boom, TB Program Focal Officer, WHO Regional Office for Europe; Francis (Kofi) Aboagye-Nyame, Director, SIAPS Program; and Dr. Joel Keravec, Head of Operations, Global Drug Facility, Stop TB Partnership, at the First Conference on Pharmaceutical Management for TB and M/XDR-TB for the WHO European Region.Photo credit: Durmuş Şahin

The highest rate of multi-drug resistant (M) and extensively drug-resistant (XDR) cases of tuberculosis (TB) is found in the World Health Organization (WHO) European Region. The Consolidated Action Plan to Prevent and Combat M/XDR-TB in the WHO European Region specifies that, by the end of 2013, all member states assure provision of an interrupted supply of quality first- and second-line medicines for treatment of all TB and M/XDR-TB patients.

Safe and rational use of these medicines is also a challenge. To deal with these demanding challenges means an increased need to strengthen pharmaceutical management, especially in the areas of second-line TB medicines management, new TB medicines, and novel treatment regimens.

Printer Friendly Version
Subscribe to RSS - who european region